cd90 immunostaining (green) of primary rat cardiac fibroblasts. Rhodamine Phalloidin (red) and Dapi (blue)
At NFB we are developing the next generation of cardiac patches and grafts with the main focus being on the use of functionalized scaffolds to regenerate infarcted myocardium and alleviating the effects of ischemia in peripheral vascular disease.
Despite significant advances in surgical and pharmacological techniques, cardiovascular disease remains statistically the most significant cause of morbidity in the developed world. One of the causes of this morbidity is that there is no technique for the regeneration of infarcted myocardium. Once the blood supply to the area in question is interrupted, the inflammatory cascade, among other mechanisms, results in the damaged tissue becoming a scar. At NFB, the goals of scaffold-based cardiac gene therapy are to minimize damage, to promote regeneration, and to modulate the ultimate fibrotic response.
Acute or chronic limb ischemia is the manifestation of systemic atherosclerosis, affecting millions of people worldwide. Medical therapies for symptomatic relief are limited and surgical or endovascular interventions are useful for some individuals, but long-term results are often disappointing. At NFB we are developing the next generation of gene delivery vehicles to promote angiogenesis and regeneration of a functional tissue in acute or chronic limb ischemia.